TABLE 1.
Demographics of study cohorts and combined data
| EMIF‐AD MBD | ADNI | METSIM | Combined | |||||
|---|---|---|---|---|---|---|---|---|
| Normal amyloid | Abnormal amyloid | Normal amyloid | Abnormal amyloid | Normal amyloid | Abnormal amyloid | Normal amyloid | Abnormal amyloid | |
| N | 87 | 74 | 54 | 32 | 27 | 3 | 168 | 109 |
| Age, years, mean ± SD | 65.9 ± 7.8ab | 66.9 ± 8.3a | 75.5 ± 5.6ad | 76.1 ± 5.6a | 61.7 ± 4.5bd | 63.7 ± 6.1 | 68.3 ± 8.4 | 69.5 ± 8.6 |
| Sex, Female (%) | 43 (49%)b | 39 (53%) | 27 (50%)d | 15 (47%) | n.s. | n.s. | 70 (42%) | 54 (50%) |
| APOE ε4, 1‐2 alleles (%) | 22 (25%)a | 44 (59%)c | 5 (9.3%)ad | 16 (50%)c | 11 (41%)d | 2 (67%) | 38 (23%)c | 62 (57%)c |
| MMSE, mean ± SD | 28.9 ± 1.2 | 28.6 ± 1.2a | 29 ± 1 | 29.2 ± 1a | 28.4 ± 1.3 | 29.3 ± 0.58 | 28.8 ± 1.2 | 28.8 ± 1.2 |
| CSF amyloid 1‐42 Z‐score, mean ± SD | 0 ± 1 | –1.4 ± 0.6ac | 0 ± 1 | –3.5 ± 0.9adc | 0 ± 1 | –1.9 ± 0.15 cd | 0 ± 0.99c | –2.1 ± 1.2c |
| CSF t‐tau Z‐score, mean ± SD | 0 ± 1 | 0.74 ± 2.4 | 0±1 | 1.1 ± 1.6c | 0 ± 1 | 0.76 ± 3.2 | 0±0.99c | 0.87 ± 2.2c |
| CSF p‐tau Z‐score, mean ± SD | 0 ± 1 | 0.26 ± 1.5a | 0 ± 1 | 1.1 ± 1.7ac | 0 ± 1 | 1.2 ± 2.7 | 0 ± 0.99c | 0.56 ± 1.6c |
| CSF t‐tau status, abnormal (%) | 13 (15%) | 28 (38%)c | 5 (9.3%) | 12 (38%)c | 3 (11%) | 1 (33%) | 21 (12%)c | 41 (38%)c |
| CSF p‐tau status, abnormal (%) | 12 (14%) | 26 (35%)ac | 8 (15%) | 19 (59%)ac | 3 (11%) | 1 (33%) | 23 (14%)c | 46 (42%)c |
Abbreviations: ADNI, Alzheimer's Disease Neuroimaging Initiative; APOE, apolipoprotein E; CSF, cerebrospinal fluid; EMIF‐AD MBD, European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery; METSIM, Metabolic Syndrome in Men; MMSE, Mini‐Mental State Examination; n.s., not included in study; p‐tau, phosphorylated tau; SD, standard deviation; t‐tau, total tau.
Statistical differences were tested with chi‐square test, Mann‐Whitney U test or Student's t‐test as appropriate. Amyloid, t‐tau and p‐tau Z‐scores were calculated relative to CN amyloid normal controls. a is P < .05 comparing ADNI and EMIF‐AD MBD participants, b is P < .05 comparing EMIF‐AD MBD and METSIM, c is P < .05 comparing amyloid abnormal and normal participants, d is P < .05 comparing ADNI and METSIM participants.